Skip to main content
Scientific Reports logoLink to Scientific Reports
. 2023 May 12;13:7761. doi: 10.1038/s41598-023-34410-6

Effect of basal metabolic rate on lifespan: a sex-specific Mendelian randomization study

Jack C M Ng 1, C Mary Schooling 1,2,
PMCID: PMC10182013  PMID: 37173352

Abstract

Observationally, the association of basal metabolic rate (BMR) with mortality is mixed, although some ageing theories suggest that higher BMR should reduce lifespan. It remains unclear whether a causal association exists. In this one-sample Mendelian randomization study, we aimed to estimate the casual effect of BMR on parental attained age, a proxy for lifespan, using two-sample Mendelian randomization methods. We obtained genetic variants strongly (p-value < 5 × 10–8) and independently (r2 < 0.001) predicting BMR from the UK Biobank and applied them to a genome-wide association study of parental attained age based on the UK Biobank. We meta-analyzed genetic variant-specific Wald ratios using inverse-variance weighting with multiplicative random effects by sex, supplemented by sensitivity analysis. A total of 178 and 180 genetic variants predicting BMR in men and women were available for father’s and mother’s attained age, respectively. Genetically predicted BMR was inversely associated with father’s and mother’s attained age (years of life lost per unit increase in effect size of genetically predicted BMR, 0.46 and 1.36; 95% confidence interval 0.07–0.85 and 0.89–1.82), with a stronger association in women than men. In conclusion, higher BMR might reduce lifespan. The underlying pathways linking to major causes of death and relevant interventions warrant further investigation.

Subject terms: Evolutionary theory, Endocrine system and metabolic diseases, Epidemiology, Medical research, Genetics research

Introduction

Metabolism has long been linked to the process of aging and longevity but the evidence from studies of their associations is not always in accordance1. Several different theories of aging related to metabolism exist particularly within a life history context, where reproductive strategies and lifespan are seen as shaped by natural selection2, such as the “rate-of-living” theory and the “free radical” theory. The “rate-of-living” theory suggests that faster metabolism accelerates aging and therefore reduces lifespan whereas the “free radical” theory suggests that oxidative stress arising from metabolism is toxic and the harm accumulates to damage body systems3. Correspondingly, on average, men have a higher metabolic rate4 and also have shorter lives than women.

Total daily energy expenditure consists of basal metabolic rate (BMR), thermic effects of food, and energy expenditure from physical activity5. BMR reflects the daily energy requirement for maintaining basic bodily functions. It is the major source of energy expenditure6 and is an important parameter for estimating daily energy requirements7.

Observational studies have suggested that higher BMR predicts mortality in young individuals8,9 but lower mortality in old individuals10. Somewhat counter-intuitively, associations that change with age at recruitment may indicate causality because each successively older age group are more strongly selected survivors of a harmful exposure11. Evidence as to whether changing BMR affects the risk of mortality is lacking. In addition, observational studies are susceptible to residual confounding, when factors affecting both BMR and mortality, such as body composition, exist. A study in mice suggested that the observational association of BMR with lifespan could be confounded by fat mass12. Notably, body composition was not adjusted for in some of the human studies assessing the association of BMR with mortality9,10. Some forms of physical activity, such as resistance training but not aerobic exercise, have been shown to increase BMR13, but cannot be comprehensively assessed and adjusted for adequately, as seen in previous human studies on the same topic9,10,14. People with metabolic disorders, such as type 2 diabetes, have a higher BMR than those without15,16 and are also at a higher risk of mortality, although a change in BMR could have occurred due to latent metabolic disruption making it look as if BMR caused the disease17,18. Aging and progression of some other medical conditions may lower BMR over time19 and increase the risk of mortality, which might also obscure the true associations. To date, no randomized controlled trial targeting BMR as a means of increasing lifespan has been conducted.

Mendelian randomization (MR) uses genetic variants (GVs) as instrumental variables to estimate the causal effect of an exposure on an outcome20. Since alleles are randomly assorted and are fixed at conception, MR studies have the advantage over conventional observational studies of being less vulnerable to confounding. MR studies of longevity have the advantage of ensuring that exposure allocation and recruitment are aligned, thereby avoiding any time-related biases21, such as selection or survival bias.

We conducted a sex-specific MR study to estimate the causal effect of BMR on parental attained age, a proxy of lifespan, because BMR differs by sex22. For validation, we also included survival to old age as an additional outcome.

Results

Genetic predictors of basal metabolic rate

We obtained 217 and 219 GVs strongly and independently predicting BMR in men and women, respectively, of which 178 and 180 were available for father’s and mother’s attained age (Supplementary Table S1). Correspondingly, these GVs explained 6.5% and 5.6% of the variance in BMR, with a mean F-statistic of 62 (range 30–363) and 61 (range 30–400) (Supplementary Table S2). Supplementary Table S3 shows the GVs predicting BMR that were associated with potential confounders. The study has power of > 80% to detect 0.59 and 0.67 years of life changed per one unit of effect size increase in genetically predicted BMR in men and women, respectively.

Association of basal metabolic rate with parental attained age

BMR was inversely associated with father’s (years of life lost per unit increase in effect size of genetically predicted BMR, 0.46 [95% confidence interval (CI) 0.07–0.85]) and mother’s attained age (years of life lost, 1.36 [95% CI 0.89–1.82]) using inverse-variance weighting (IVW) with multiplicative random effects, with evidence of stronger associations in women than men (Table 1). Sensitivity analyses gave directionally similar results. MR-Egger intercept tests did not suggest the presence of directional pleiotropy. I2GX ranged from 0.77 to 0.83 in all MR-Egger analyses.

Table 1.

Mendelian randomization of basal metabolic rate (Neale Lab) on father's and mother's attained age (Pilling et al.). CI: confidence interval; GV: genetic variant; IVW: inverse-variance weighting; LL: lower limit; MR: Mendelian randomization; MR-RAPS: Mendelian Randomization Robust Adjusted Profile Score; MR-PRESSO: Mendelian Randomization Pleiotropy Residual Sum and Outlier; SE: standard error; UL: upper limit; WM: weighted median.

Exposure Outcome Selection of GVs No. of GVs MR method Beta Years of life lost p-value Cochran's Q MR-Egger Outlier detected by MR-PRESSO Sex difference for years of life lost
Trait Sex Trait Sex Estimate SE 95% CI LL 95% CI UL Estimate SE 95% CI LL 95% CI UL Statistic p-value Intercept Intercept p-value I2GX z statistic p-value
Men
Basal metabolic rate Men Father's attained age Men All 178 IVW (random) 0.020 0.009 0.003 0.037 0.46 0.20 0.07 0.85 0.021 360.839 1.14E−14 2.894 0.004
All 178 WM 0.022 0.010 0.002 0.042 0.50 0.24 0.04 0.96 0.035 1.946 0.052
All 178 MR-Egger 0.004 0.023 –0.041 0.049 0.10 0.52 –0.93 1.12 0.855 359.698 1.07E−14 0.001 0.455 0.826 1.300 0.194
All 178 MR-RAPS 0.021 0.006 0.009 0.033 0.47 0.14 0.20 0.75 0.001 4.198 2.70E05
All 175 MR–PRESSO (corrected) 0.022 0.008 0.007 0.037 0.50 0.18 0.15 0.85 0.005 rs112875651, rs3184504, rs62396185 2.869 0.004
Exclusion of potentially confounded GVs 162 IVW (random) 0.019 0.009 0.001 0.038 0.44 0.22 0.01 0.86 0.044 327.644 1.89E−13 2.739 0.006
Exclusion of potentially confounded GVs 162 WM 0.005 0.011 −0.017 0.026 0.11 0.25 −0.39 0.60 0.675 3.330 0.001
Exclusion of potentially confounded GVs 162 MR-Egger −0.007 0.025 −0.057 0.043 −0.16 0.58 −1.30 0.98 0.783 325.157 2.51E−13 0.001 0.269 0.773 1.947 0.052
Exclusion of potentially confounded GVs 162 MR-RAPS 0.020 0.007 0.007 0.033 0.45 0.15 0.15 0.75 0.003 3.930 8.49E05
Exclusion of potentially confounded GVs 159 MR-PRESSO (corrected) 0.021 0.008 0.005 0.038 0.49 0.19 0.11 0.86 0.012 rs112875651, rs3184504, rs62396185 2.877 0.004
Women
Basal metabolic rate Women Mother's attained age Women All 180 IVW (random) 0.052 0.009 0.034 0.071 1.36 0.24 0.89 1.82 1.32E08 357.236 5.93E–14
All 180 WM 0.048 0.011 0.025 0.070 1.23 0.30 0.65 1.82 3.32E05
All 180 MR-Egger 0.046 0.026 –0.004 0.096 1.19 0.66 –0.10 2.49 0.071 357.092 4.31E–14 0.0002 0.789 0.829
All 180 MR-RAPS 0.054 0.007 0.041 0.067 1.40 0.17 1.07 1.74 2.22E16
All 177 MR-PRESSO (corrected) 0.051 0.009 0.034 0.068 1.32 0.22 0.88 1.76 1.77E08 rs10774624, rs2102278, rs9843653
Exclusion of potentially confounded GVs 161 IVW (random) 0.052 0.010 0.033 0.072 1.35 0.26 0.85 1.86 1.34E07 308.741 1.62E–11
Exclusion of potentially confounded GVs 161 WM 0.056 0.012 0.032 0.081 1.46 0.32 0.84 2.08 4.40E06
Exclusion of potentially confounded GVs 161 MR-Egger 0.065 0.029 0.008 0.121 1.67 0.74 0.22 3.13 0.024 308.331 1.27E–11 –0.0004 0.645 0.771
Exclusion of potentially confounded GVs 161 MR-RAPS 0.054 0.007 0.040 0.068 1.40 0.19 1.03 1.77 7.33E14
Exclusion of potentially confounded GVs 159 MR-PRESSO (corrected) 0.053 0.009 0.035 0.072 1.38 0.24 0.90 1.86 6.95E08 rs10774624, rs2102278

Overall, BMR was inversely associated with parental attained age (Supplementary Table S4).

Association of basal metabolic rate with survival to 99th and 90th percentile of ages

BMR was not associated with survival to the 99th or 90th percentile of ages using IVW with multiplicative random effects in both men (odds ratio for 99th percentile of age per unit increase in effect size of genetically predicted BMR, 0.92 [95% CI 0.76–1.11]; odds ratio for 90th percentile of age, 0.91 [95% CI 0.80–1.03]) and women (odds ratio for 99th percentile of age, 0.97 [95% CI 0.80–1.18]; odds ratio for 90th percentile of age, 0.94 [95% CI 0.82–1.07]), although the associations were in the direction of higher BMR reducing survival (Table 2). Sensitivity analyses gave similar results. MR-Egger intercept tests did not suggest the presence of directional pleiotropy. I2GX ranged from 0.78 to 0.87 in all MR-Egger analyses.

Table 2.

Mendelian randomization of basal metabolic rate (Neale Lab) on survival to old age (Deelen et al.). CI: confidence interval; GV: genetic variant; IVW: inverse-variance weighting; LL: lower limit; MR: Mendelian randomization; MR-RAPS: Mendelian Randomization Robust Adjusted Profile Score; MR-PRESSO: Mendelian Randomization Pleiotropy Residual Sum and Outlier; SE: standard error; UL: upper limit; WM: weighted median.

Exposure Outcome Selection of GVs No. of GVs MR method Beta Odds ratio p-value Cochran's Q MR-Egger Outlier detected Sex difference
Trait Sex Trait Sex Estimate SE 95% CI LL 95% CI UL Estimate 95% CI LL 95% CI UL Statistic p-value Intercept Intercept p-value I2GX by MR-PRESSO z statistic p-value
Men
Basal metabolic rate Men Survival to 99th percentile of age Overall All 202 IVW (random) −0.087 0.095 −0.275 0.100 0.916 0.760 1.105 0.359 259.518 0.003 0.420 0.674
All 202 WM −0.217 0.136 −0.484 0.050 0.805 0.617 1.051 0.111 1.098 0.272
All 202 MR-Egger −0.339 0.280 −0.888 0.210 0.713 0.412 1.234 0.226 258.342 0.003 0.008 0.340 0.838 0.010 0.992
All 202 MR-RAPS −0.089 0.085 −0.256 0.078 0.914 0.774 1.081 0.294 0.474 0.636
All 201 MR-PRESSO (corrected) −0.062 0.093 −0.245 0.122 0.940 0.783 1.130 0.510 rs768023 0.242 0.809
Exclusion of potentially confounded GVs 186 IVW (random) −0.042 0.102 −0.241 0.158 0.959 0.786 1.172 0.684 231.722 0.011 0.785 0.433
Exclusion of potentially confounded GVs 186 WM −0.185 0.145 −0.468 0.099 0.831 0.626 1.104 0.202 1.622 0.105
Exclusion of potentially confounded GVs 186 MR-Egger −0.126 0.315 −0.744 0.491 0.881 0.475 1.634 0.689 231.621 0.010 0.003 0.776 0.791 0.461 0.645
Exclusion of potentially confounded GVs 186 MR-RAPS −0.042 0.093 −0.224 0.139 0.958 0.799 1.149 0.646 0.864 0.388
Exclusion of potentially confounded GVs 185 MR-PRESSO (corrected) −0.011 0.099 −0.206 0.185 0.989 0.814 1.203 0.915 rs768023 0.755 0.450
Basal metabolic rate Men Survival to 90th percentile of age Overall All 204 IVW (random) −0.098 0.063 −0.221 0.026 0.907 0.801 1.026 0.120 288.099 7.92E−05 0.381 0.704
All 204 WM −0.048 0.086 −0.217 0.122 0.953 0.805 1.129 0.581 - - - - - - 0.071 0.943
All 204 MR-Egger −0.313 0.179 −0.665 0.039 0.731 0.514 1.040 0.081 285.783 9.46E−05 0.007 0.201 0.832 - 0.422 0.673
All 204 MR-RAPS −0.100 0.054 −0.205 0.005 0.905 0.814 1.005 0.061 0.442 0.659
All 203 MR-PRESSO (corrected) −0.082 0.062 −0.203 0.040 0.921 0.816 1.040 0.186 rs768023 0.622 0.534
Exclusion of potentially confounded GVs 188 IVW (random) −0.104 0.068 −0.236 0.029 0.902 0.789 1.030 0.126 262.112 0.0002 0.793 0.428
Exclusion of potentially confounded GVs 188 WM −0.010 0.092 −0.189 0.170 0.991 0.828 1.185 0.917 0.491 0.623
Exclusion of potentially confounded GVs 188 MR-Egger −0.305 0.201 −0.699 0.089 0.737 0.497 1.093 0.129 260.522 0.0003 0.006 0.287 0.783 1.035 0.301
Exclusion of potentially confounded GVs 188 MR-RAPS −0.106 0.058 −0.220 0.007 0.899 0.802 1.008 0.067 0.934 0.350
Exclusion of potentially confounded GVs 187 MR-PRESSO (corrected) −0.085 0.066 −0.215 0.046 0.919 0.806 1.047 0.201 rs768023 0.796 0.426
Women
Basal metabolic rate Women Survival to 99th percentile of age Overall All 202 IVW (random) −0.029 0.100 −0.225 0.167 0.971 0.798 1.182 0.770 249.285 0.012
All 202 WM −0.0003 0.143 −0.280 0.280 0.9997 0.756 1.322 0.998
All 202 MR-Egger −0.335 0.293 −0.909 0.238 0.715 0.403 1.269 0.252 247.751 0.012 0.009 0.266 0.867
All 202 MR-RAPS −0.030 0.091 −0.209 0.149 0.971 0.812 1.161 0.743
All 202 MR-PRESSO* −0.029 0.100 −0.227 0.168 0.971 0.797 1.183 0.770
Exclusion of potentially confounded GVs 183 IVW (random) 0.074 0.107 −0.136 0.284 1.077 0.873 1.329 0.490 218.214 0.034
Exclusion of potentially confounded GVs 183 WM 0.157 0.153 −0.143 0.457 1.170 0.867 1.579 0.305
Exclusion of potentially confounded GVs 183 MR-Egger 0.087 0.338 −0.575 0.749 1.091 0.563 2.114 0.797 218.212 0.031 –0.0004 0.968 0.836
Exclusion of potentially confounded GVs 183 MR-RAPS 0.076 0.100 −0.120 0.271 1.079 0.887 1.311 0.447
Exclusion of potentially confounded GVs 182 MR-PRESSO (corrected) 0.098 0.105 −0.109 0.305 1.103 0.896 1.356 0.353 rs599004
Basal metabolic rate Women Survival to 90th percentile of age Overall All 203 IVW (random) −0.063 0.067 −0.194 0.067 0.939 0.824 1.070 0.343 277.242 0.0003
All 203 WM −0.057 0.093 −0.239 0.126 0.945 0.787 1.134 0.542
All 203 MR-Egger −0.202 0.193 −0.580 0.177 0.817 0.560 1.194 0.297 276.441 0.0003 0.004 0.446 0.851
All 203 MR-RAPS −0.065 0.058 −0.178 0.048 0.937 0.837 1.050 0.262
All 201 MR-PRESSO (corrected) −0.027 0.063 −0.152 0.098 0.974 0.859 1.103 0.673 rs3800228, rs599004
Exclusion of potentially confounded GVs 184 IVW (random) −0.026 0.071 −0.164 0.113 0.974 0.848 1.119 0.714 237.752 0.004
Exclusion of potentially confounded GVs 184 WM 0.056 0.098 −0.136 0.248 1.058 0.873 1.281 0.568
Exclusion of potentially confounded GVs 184 MR-Egger 0.002 0.218 −0.426 0.430 1.002 0.653 1.537 0.994 237.728 0.003 –0.0008 0.894 0.812
Exclusion of potentially confounded GVs 184 MR-RAPS −0.026 0.063 −0.150 0.097 0.974 0.861 1.102 0.674
Exclusion of potentially confounded GVs 183 MR-PRESSO (corrected) −0.009 0.069 −0.145 0.126 0.991 0.865 1.135 0.895 rs599004

Discussion

Using MR and outcomes that obviate survival bias, we have shown that genetically higher BMR was associated with reduced parental attained age. Validation using survival to old age also showed directionally similar results. Our results are consistent with observational studies in younger individuals that reported a higher BMR being positively associated mortality8,9 and some theories of ageing14.

From the perspective of disease etiology, cancer and cardiovascular diseases are two leading causes of death worldwide23,24 and contribute substantially to years of life lost24,25. In an MR study, BMR was shown to increase the risk of cancer26, which supports our findings. Excessive harmful reactive oxygen species produced at a higher rate of metabolism that cannot be compensated by timely cell repair are thought to be the underlying mechanism27. The role of BMR in the development of cardiovascular diseases is not well studied. However, in observational studies BMR is reported to be positively associated with systolic blood pressure28,29, an established risk factor for cardiovascular diseases, although causality between BMR and systolic blood pressure could not be ascertained. Some anti-obesity drugs that act via raising BMR, e.g., thyroid hormone and melanocortin-4 receptor agonists, have been reported to cause cardiovascular side effects30,31. Postulated mechanisms linking higher BMR and systolic blood pressure include increased cardiac output28 and excessive production of reactive oxygen species29.

We found an inverse association of BMR with parental attained age in both men and women with a stronger association in women than men. Investigation of the downstream effects of BMR may gain more insight. A sex-specific effect may have clinical implications because muscle mass, a readily modifiable component that contributes substantially to BMR32, differs by sex22. At the same body mass index, men have more muscle mass and less fat mass than women. Whether the disadvantage at the starting line in men of having more muscle mass could be compensated by the weaker effect of BMR on lifespan compared to women throughout their life is unclear.

BMR is a possible target of intervention for lifespan in several ways. For lifestyle aspects, resistance training has been suggested as increasing BMR33, possibly through building muscle mass34. Caloric restriction reduces BMR35 and appears to promote longer lifespan36, as also in line with the viewpoint of tradeoff between growth, reproduction, and longevity in evolutionary biology37,38. In animal studies, it has recently been suggested that metabolism may interact with life history traits, specifically growth and reproduction, to act as a constraint on maximizing fitness, i.e., lifetime reproduction39. During these processes, a higher metabolic rate was observed to be associated with reduced longevity. Protein intake is reported to raise insulin-like growth factor 140, a hormone responsible for growth, which also increases BMR41. For therapies that alter hormonal levels, exogenous testosterone has been shown to increase BMR, largely through building muscle mass42. Raising thyroid hormones also leads to an increase in BMR43. Climate change towards global warming may have an impact on BMR. Prolonged heat exposure may impair thermoregulation, a process to maintain normal core temperature of the body by increasing BMR at low ambient temperature and vice versa44, thus causing a rise in core temperature45,46. BMR increases with core temperature47, although protein damage can occur and eventually inhibits BMR45.

The validity of an MR study relies on a few key assumptions. First, it requires GVs to be strongly associated with the exposure. To assure this, we only selected GVs associated with BMR at genome-wide significance (p-value < 5 × 10–8). Also, all GVs predicting BMR had an F-statistic ≥ 30, which is greater than the rule-of-thumb value of 10 for a non-weak instrument48. The I2GX value for MR-Egger was approximately 0.9, which also reflects an overall non-weak set of instruments49. Second, it requires GVs not to be associated with the confounders of the GV-outcome association. Although it was not possible for us to perform an exhaustive check on all potential confounders, we assessed the association of GVs with five key potential confounders related to lifestyle and socioeconomic position in the UK Biobank and excluded relevant GVs in sensitivity analysis. The results were largely consistent. Third, it requires GVs to affect the outcome only via the exposure of interest, which can be violated in different ways. A GV can exhibit horizontal pleiotropy, i.e., influencing multiple exposures, which in turn affects the outcome through different pathways. To address this issue, we conducted sensitivity analysis using different MR methods, including the weighted median, MR-Egger, and MR Pleiotropy RESidual Sum and Outlier (MR-PRESSO), which gave directionally similar results. MR-Egger intercept tests also did not suggest the presence of directional horizontal pleiotropy. Besides, selection bias in MR can distort associations if the GV (GV predicting BMR) or the exposure itself (BMR) affects survival, which precludes subjects from being recruited into the underlying genome-wide association studies (GWASs)50. This is an inherent problem of MR studies because of the time lag between randomization and recruitment into the study21. Selection bias in MR can also occur when a competing risk that shares common causes with the outcome of interest also affects survival50. However, our MR analysis benefits from using parental attained age as an outcome, which is not subject to such concerns.

This study has certain limitations. First, data on BMR was derived from impedance measurement using a body composition analyzer instead of being measured using the gold standard, indirect calorimetry. However, good estimation may be achieved by including body composition in the prediction formula51. Second, weak instrument bias may be present, which generally biases MR estimates towards the null in two-sample MR, provided that there is no sample overlap52. In our study, both the exposure and primary outcome used participants from the UK Biobank. However, the use of IVW and weighted median methods in two-sample MR using single sample are considered acceptable for large-sample studies53. MR Robust Adjusted Profile Score (MR-RAPS) complemented the results under possible weak instrument bias. In contrast, the MR-Egger estimate should be interpreted with caution in view of the insufficiently large I2GX value53, with a maximum of 0.89 in the analysis of parental attained age. However, most MR-Egger estimates were directionally similar to the IVW one. Third, we assumed a linear association between BMR and parental attained age. With summary-level data only, we were unable to verify this assumption. Fourth, population stratification can introduce genetic confounding. However, the underlying GWASs we used restricted analysis only to individuals of European descent. Besides, they were also adjusted for principal components for ancestry. Fifth, the MR estimates in our study represent only the lifelong effect of BMR on parental attained age. Whether short-term interventions on BMR could produce similar effects requires further investigation. Sixth, our findings may not be generalized to populations other than those of European descent. However, causes should be consistent across populations though relevancy is an issue54, especially because body composition across population varies. Seventh, canalization refers to the developmental compensation arisen from the effect of the GV. However, its existence in our study is unknown. Further, it also biases MR estimates towards the null, which could not explain the observed associations. Eighth, sex-specific GWASs were available for the exposure and primary outcome but not the additional outcome.

In conclusion, our results showed that higher BMR might reduce lifespan in a sex-specific manner. This might have a practical implication on recommending the optimal level of physical activity, especially resistance training and muscle mass building as well as dietary patterns, hormonal treatments, and environmental factors that raise BMR. The underlying mechanism by which BMR is related to major causes of death is worth further investigation.

Methods

We conducted an MR study of the association of BMR with parental attained age as the primary outcome using a two-sample MR approach by applying genetic predictors of the exposure to GWASs of outcomes with summary statistics. As an instrumental variable analysis, MR requires fulfillment of several important assumptions to give valid results. First, the GVs must be strongly associated with the exposure. Second, the GVs must not confound the GV-outcome association. Third, the GVs must be independent of the outcome given the exposure. In particular, given, we used two-sample methods applied in a one-sample study, albeit, in a large study, we checked for validity of the estimates53 and we additionally used survival to old age as an additional outcome, because the cases does not overlap with source study for the exposure.

Data source

Basal metabolic rate

Genetic predictors of BMR were retrieved from UK Biobank summary statistics provided by Neale Lab55. The UK Biobank is a large-scale population-based prospective study, which aimed to enroll > 500,000 participants aged between 40 and 69 years from 2006 to 2010 in Great Britain56. BMR (in kilojoule) was estimated using a body composition analyzer (Tanita BC418MA Body Composition Analyzer) (https://biobank.ctsu.ox.ac.uk/crystal/refer.cgi?id=1421), which is based on Dual-energy X-ray absorptiometry using bioelectrical impedance analysis (https://www.tanita.com/es/.downloads/download/?file=855638086&fl=en_US). The analyzer provides BMR derived mainly from fat-free mass using a proprietary regression formula, which highly correlates to that measured using indirect calorimetry (r = 0.9, p < 0.0001) (https://www.tanita.com/es/.downloads/download/?file=855638086&fl=en_US). The Neale Lab obtained quality-controlled sex-specific genetic associations in unrelated participants with BMR using multivariable linear regression, adjusted for age, age x age, and the first 20 principal components in up to 361,194 individuals (54% women) of white British ancestry. The estimates were in standard deviations from rank-inverse-normalization of residuals of the regression (phenotype code, 23105_irnt).

Parental attained age

Genetic associations with parental (father’s and mother’s) attained age, where the age of parents (in years) was reported by their offspring, were retrieved from a GWAS of lifespan57. This GWAS analyzed attained age for 415,311 fathers and 412,937 mothers of participants of European descent from the UK Biobank56 after excluding those who reported themselves as adopted or had premature death of parents defined as a father who died before 46 years old and mother who died before 57 years old. The genetic associations were adjusted for age, sex, assessment centre, and array type. The estimates were expressed as rank-normalized Martingale residuals of the Cox’s proportional hazards regression, with a positive value representing a reduced attained age.

Survival to the 90th and 99th percentile of ages

Genetic associations with odds of survival to the 90th and 99th percentile of ages or above compared to the 60th percentile of age or below, where percentiles of age were country-, sex-, and birth cohort-specific, were retrieved from a meta-analysis of GWASs of survival to old age58. This study contains 11,262 cases of survival to the 90th percentile of age, 3,484 cases of survival to the 99th percentile of age, and 25,483 controls of survival to the 60th percentile of age in people of European descent. The genetic associations were adjusted for clinical site, known family relationships, and/or the first four principal components. The estimates were in log odds ratios of survival.

Selection of genetic variants

We excluded GVs for BMR that are non-biallelic, rare (minor allele frequency < 0.01), or not in Hardy–Weinberg equilibrium (p-value for Chi-squared test < 0.05). Only GVs that predicted BMR at p-value < 5 × 10–8 were retained. We then obtained the uncorrelated GVs, i.e., GVs not in linkage disequilibrium, with r2 < 0.001 using the “clump_data” function in the “TwoSampleMR” R package59. GVs unavailable for the outcome were discarded.

Assessment of confounding

We examined whether the GVs for BMR were associated with five key potential confounders of the GVs on outcome related to socioeconomic status and lifestyle attributes, including a measure of deprivation (Townsend index (phenotype code, 189)), age at completion of full-time education (phenotype code, 845), number of days per week walked for 10 min or more (phenotype code, 864), current smoking (phenotype code, 1239), and alcohol intake frequency (phenotype code, 1558) using summary statistics from the UK Biobank provided by the Neale Lab55, at Bonferroni-corrected significance, i.e., 0.05 / (number of GVs x number of traits).

Statistical analysis

We harmonized the effect allele of a GV for exposure and outcome based on the allele letters in general. The Neale Lab reported the reference alleles on the forward strand55. Pilling et al. and Deelen et al. did not report the strand orientation but provided the effect allele frequency57,58. We therefore only kept palindromic GVs with effect allele frequency ≤ 0.45 and ≥ 0.55 (i.e., not close to 0.50) in the analysis.

GV-specific Wald estimates were calculated as the ratio of the effect size of the GV-outcome association to that of the GV-exposure association60. The corresponding standard error was approximated from the first term of Fieller’s theorem61.

We computed the F-statistic, which reflects the strength of genetic instrument, for each GV using an approximation, i.e., by dividing the squared effect size by the squared standard error of GV-exposure association49. An F-statistic of > 10 indicates that the genetic instrument is not weak.

In the primary analysis, we meta-analyzed GV-specific Wald estimates using IVW with multiplicative random effects, which assumed no measurement error for the exposure49 and balanced pleiotropy62, using the “MendelianRandomization” R package63. The Cochran’s Q statistic quantifies the hetereogeneity among the genetic instruments and serves as an indicator of potential horizontal pleiotropy59,64.

As a sensitivity analysis to address potential horizontal pleiotropy, where GVs predicting the exposure of interest affect the outcome via pathways other than the exposure of interest itself, we employed the weighted median and MR-Egger methods using the “MendelianRandomization” R package63, MR-PRESSO method using the “MRPRESSO” R package (with 10,000 simulations)65, and MR-RAPS method using the “mr.raps” R package66. The weighted median method provides a valid estimate when > 50% of weight is from valid GVs67. The MR-Egger method provides a valid estimate as long as the “instrument strength independent of direct effect”49,68 and “no measurement error for the exposure” assumptions hold49. A non-zero MR-Egger intercept indicates the presence of directional pleiotropy or violation of the “instrument strength independent of direct effect” assumption, which biases the IVW estimate49. The I2GX value of MR-Egger reflects the overall strength of the genetic instrument set and a higher value close to unity is more desirable in order to minimize the regression dilution bias arisen from measurement error49. When conducting one-sample MR, estimates should be valid with the sample size here, as long as the I2GX > 97% for MR-Egger53. The MR-PRESSO method adopts the IVW method but detects directional pleiotropy statistically and corrects it by removing outliers65. The MR-RAPS method assumes balanced pleiotropy and that the pleiotropic effects are normally distributed66. It also takes into account measurement error for the exposure that can lead to weak instrument bias.

We repeated all analyses by removing GVs associated with potential confounders at Bonferroni-corrected significance as additional sensitivity analysis.

To visualize the results for the primary outcome, we additionally presented the MR estimates by converting the rank-normalized Martingale residuals into years of life lost using an established approximation, i.e., multiply by 2.2869 and 2.5863 for fathers and mothers, respectively, to account for the genetic associations given offspring only share half their genetic endowment with each parent, then multiply by 10 in accordance with a long-standing actuarial rule of thumb recently verified69. To obtain the overall associations, we also meta-analyzed the sex-specific estimates of years of life lost.

Any sex difference in years of life lost was assessed using a z-test70.

Post hoc power calculations were performed using an online calculator71, which is based on the approximation that the sample size for an MR study is the sample size for exposure on outcome divided by the proportion of variance in exposure explained by the GVs72. The proportion of variance in BMR explained by each GV was estimated by an approximation as (effect size of the genetic associations with BMR)2 × 2 x minor allele frequency x (1 – minor allele frequency)73. All GV-specific proportions of variance were summated to give the overall one.

All statistical analyses were conducted using R (Version 4.0.3, The R Foundation for Statistical Computing Platform, Vienna, Austria).

Eithics approval and consent to participate

We only used publicly available summary-level data in the current study. No original data was collected. Ethical approval including written informed consent from individual participants can be found in the original publications.

Supplementary Information

Supplementary Tables. (107.5KB, xlsx)

Acknowledgements

The authors thank the Neale Lab, Pilling et al., and Deelen et al. for providing the summary-level data.

Abbreviations

BMR

Basal metabolic rate

CI

Confidence interval

GV

Genetic variant

GWAS

Genome-wide association study

IVW

Inverse-variance weighting

MR

Mendelian randomization

MR-RAPS

Mendelian randomization robust adjusted profile score

MR-PRESSO

Mendelian randomization pleiotropy residual sum and outlier

Author contributions

J.C.M.N.: methodology, formal analysis, writing—original draft, writing—review and editing, approval of the final manuscript. C.M.S.: conceptualization, methodology, validation, supervision, writing—review and editing, approval of the final manuscript.

Data availability

The datasets generated during and/or analyzed during the current study are available from the website of the Neale Lab (http://www.nealelab.is/uk-biobank/), a GWAS of parental attained age (https://figshare.com/articles/dataset/Plling_et_al_2017_UKB_parents_attained_age_GWAS/5439382/2), and a GWAS of survival to old age (https://www.ebi.ac.uk/gwas/publications/31413261).

Competing interests

The authors declare no competing interests.

Footnotes

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

The online version contains supplementary material available at 10.1038/s41598-023-34410-6.

References

  • 1.Bartke A, Brannan S, Hascup E, Hascup K, Darcy J. Energy metabolism and aging. World J. Mens Health. 2021;39:222–232. doi: 10.5534/wjmh.200112. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Stearns, S. C. The Evolution of Life Histories. (Oxford University Press, 1992).
  • 3.Park DC, Yeo SG. Aging. Korean J. Audiol. 2013;17:39–44. doi: 10.7874/kja.2013.17.2.39. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Tooze JA, et al. Total daily energy expenditure among middle-aged men and women: The OPEN Study. Am. J. Clin. Nutr. 2007;86:382–387. doi: 10.1093/ajcn/86.2.382. [DOI] [PubMed] [Google Scholar]
  • 5.Levine JA. Measurement of energy expenditure. Public Health Nutr. 2005;8:1123–1132. doi: 10.1079/PHN2005800. [DOI] [PubMed] [Google Scholar]
  • 6.Shetty P. Energy requirements of adults. Public Health Nutr. 2005;8:994–1009. doi: 10.1079/PHN2005792. [DOI] [PubMed] [Google Scholar]
  • 7.Ferro-Luzzi A. The conceptual framework for estimating food energy requirement. Public Health Nutr. 2005;8:940–952. doi: 10.1079/PHN2005789. [DOI] [PubMed] [Google Scholar]
  • 8.Jumpertz R, et al. Higher energy expenditure in humans predicts natural mortality. J. Clin. Endocrinol. Metab. 2011;96:E972–976. doi: 10.1210/jc.2010-2944. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Ruggiero C, et al. High basal metabolic rate is a risk factor for mortality: The Baltimore Longitudinal Study of Aging. J. Gerontol. A Biol. Sci. Med. Sci. 2008;63:698–706. doi: 10.1093/gerona/63.7.698. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Han F, et al. Association between basal metabolic rate and all-cause mortality in a prospective cohort of southern Chinese adults. Front Physiol. 2021;12:790347. doi: 10.3389/fphys.2021.790347. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Schooling CM. Selection bias in population-representative studies? A commentary on Deaton and Cartwright. Soc. Sci. Med. 2018;210:70. doi: 10.1016/j.socscimed.2018.04.047. [DOI] [PubMed] [Google Scholar]
  • 12.Duarte LC, Speakman JR. Low resting metabolic rate is associated with greater lifespan because of a confounding effect of body fatness. Age (Dordr) 2014;36:9731. doi: 10.1007/s11357-014-9731-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.MacKenzie-Shalders K, Kelly JT, So D, Coffey VG, Byrne NM. The effect of exercise interventions on resting metabolic rate: A systematic review and meta-analysis. J. Sports Sci. 2020;38:1635–1649. doi: 10.1080/02640414.2020.1754716. [DOI] [PubMed] [Google Scholar]
  • 14.Ruggiero C, Ferrucci L. The endeavor of high maintenance homeostasis: resting metabolic rate and the legacy of longevity. J. Gerontol. A Biol. Sci. Med. Sci. 2006;61:466–471. doi: 10.1093/gerona/61.5.466. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Huang KC, Kormas N, Steinbeck K, Loughnan G, Caterson ID. Resting metabolic rate in severely obese diabetic and nondiabetic subjects. Obes. Res. 2004;12:840–845. doi: 10.1038/oby.2004.101. [DOI] [PubMed] [Google Scholar]
  • 16.Bitz C, et al. Increased 24-h energy expenditure in type 2 diabetes. Diabetes Care. 2004;27:2416–2421. doi: 10.2337/diacare.27.10.2416. [DOI] [PubMed] [Google Scholar]
  • 17.Cohrs CM, et al. Dysfunction of persisting β cells is a key feature of early type 2 diabetes pathogenesis. Cell Rep. 2020;31:107469. doi: 10.1016/j.celrep.2020.03.033. [DOI] [PubMed] [Google Scholar]
  • 18.Ucok K, et al. Do patients with newly diagnosed type 2 diabetes have impaired physical fitness, and energy expenditures? Neth. J. Med. 2015;73:276–283. [PubMed] [Google Scholar]
  • 19.Zampino M, AlGhatrif M, Kuo PL, Simonsick EM, Ferrucci L. Longitudinal changes in resting metabolic rates with aging are accelerated by diseases. Nutrients. 2020;12:1. doi: 10.3390/nu12103061. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Didelez V, Sheehan N. Mendelian randomization as an instrumental variable approach to causal inference. Stat. Methods Med. Res. 2007;16:309–330. doi: 10.1177/0962280206077743. [DOI] [PubMed] [Google Scholar]
  • 21.Hernan MA, Sauer BC, Hernandez-Diaz S, Platt R, Shrier I. Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses. J. Clin. Epidemiol. 2016;79:70–75. doi: 10.1016/j.jclinepi.2016.04.014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Arciero PJ, Goran MI, Poehlman ET. Resting metabolic rate is lower in women than in men. J. Appl. Physiol. 1993;1985(75):2514–2520. doi: 10.1152/jappl.1993.75.6.2514. [DOI] [PubMed] [Google Scholar]
  • 23.Lin L, et al. Global, regional, and national cancer incidence and death for 29 cancer groups in 2019 and trends analysis of the global cancer burden, 1990–2019. J. Hematol. Oncol. 2021;14:197. doi: 10.1186/s13045-021-01213-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Roth GA, et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019: Update From the GBD 2019 Study. J. Am. Coll. Cardiol. 2020;76:2982–3021. doi: 10.1016/j.jacc.2020.11.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Kocarnik JM, et al. Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: A systematic analysis for the global burden of disease study 2019. JAMA Oncol. 2022;8:420–444. doi: 10.1001/jamaoncol.2021.6987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Ng JCM, Schooling CM. Effect of basal metabolic rate on cancer: A mendelian randomization study. Front Genet. 2021;12:735541. doi: 10.3389/fgene.2021.735541. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Dröge W. Free radicals in the physiological control of cell function. Physiol. Rev. 2002;82:47–95. doi: 10.1152/physrev.00018.2001. [DOI] [PubMed] [Google Scholar]
  • 28.Sriram N, Hunter GR, Fisher G, Brock DW. Resting energy expenditure and systolic blood pressure relationships in women across 4.5 years. J. Clin. Hypertens. (Greenwich). 2014;16:172–176. doi: 10.1111/jch.12256. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Snodgrass JJ, Leonard WR, Sorensen MV, Tarskaia LA, Mosher MJ. The influence of basal metabolic rate on blood pressure among indigenous Siberians. Am. J. Phys. Anthropol. 2008;137:145–155. doi: 10.1002/ajpa.20851. [DOI] [PubMed] [Google Scholar]
  • 30.Adan RA. Mechanisms underlying current and future anti-obesity drugs. Trends Neurosci. 2013;36:133–140. doi: 10.1016/j.tins.2012.12.001. [DOI] [PubMed] [Google Scholar]
  • 31.Oliveira V, Kwitek AE, Sigmund CD, Morselli LL, Grobe JL. Recent advances in hypertension: Intersection of metabolic and blood pressure regulatory circuits in the central nervous system. Hypertension. 2021;77:1061–1068. doi: 10.1161/HYPERTENSIONAHA.120.14513. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Johnstone AM, Murison SD, Duncan JS, Rance KA, Speakman JR. Factors influencing variation in basal metabolic rate include fat-free mass, fat mass, age, and circulating thyroxine but not sex, circulating leptin, or triiodothyronine. Am. J. Clin. Nutr. 2005;82:941–948. doi: 10.1093/ajcn/82.5.941. [DOI] [PubMed] [Google Scholar]
  • 33.Tresierras MA, Balady GJ. Resistance training in the treatment of diabetes and obesity: mechanisms and outcomes. J. Cardiopulm. Rehabil. Prev. 2009;29:67–75. doi: 10.1097/HCR.0b013e318199ff69. [DOI] [PubMed] [Google Scholar]
  • 34.Joanisse S, et al. Recent advances in understanding resistance exercise training-induced skeletal muscle hypertrophy in humans. F1000Res. 2020;9:1. doi: 10.12688/f1000research.21588.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Ravussin E, et al. A 2-year randomized controlled trial of human caloric restriction: Feasibility and effects on predictors of health span and longevity. J. Gerontol. A Biol. Sci. Med. Sci. 2015;70:1097–1104. doi: 10.1093/gerona/glv057. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Speakman JR, Mitchell SE. Caloric restriction. Mol Aspects Med. 2011;32:159–221. doi: 10.1016/j.mam.2011.07.001. [DOI] [PubMed] [Google Scholar]
  • 37.Wells JCK, Nesse RM, Sear R, Johnstone RA, Stearns SC. Evolutionary public health: Introducing the concept. Lancet. 2017;390:500–509. doi: 10.1016/S0140-6736(17)30572-X. [DOI] [PubMed] [Google Scholar]
  • 38.Schooling CM. Tachykinin neurokinin 3 receptor antagonists: A new treatment for cardiovascular disease? Lancet. 2017;390:709–711. doi: 10.1016/S0140-6736(16)31648-8. [DOI] [PubMed] [Google Scholar]
  • 39.White CR, Alton LA, Bywater CL, Lombardi EJ, Marshall DJ. Metabolic scaling is the product of life-history optimization. Science. 2022;377:834–839. doi: 10.1126/science.abm7649. [DOI] [PubMed] [Google Scholar]
  • 40.Kazemi A, Speakman JR, Soltani S, Djafarian K. Effect of calorie restriction or protein intake on circulating levels of insulin like growth factor I in humans: A systematic review and meta-analysis. Clin. Nutr. 2020;39:1705–1716. doi: 10.1016/j.clnu.2019.07.030. [DOI] [PubMed] [Google Scholar]
  • 41.Swanson EM, Dantzer B. Insulin-like growth factor-1 is associated with life-history variation across Mammalia. Proc. Biol. Sci. 2014;281:20132458. doi: 10.1098/rspb.2013.2458. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Welle S, Jozefowicz R, Forbes G, Griggs RC. Effect of testosterone on metabolic rate and body composition in normal men and men with muscular dystrophy. J. Clin. Endocrinol. Metab. 1992;74:332–335. doi: 10.1210/jcem.74.2.1730811. [DOI] [PubMed] [Google Scholar]
  • 43.Mullur R, Liu YY, Brent GA. Thyroid hormone regulation of metabolism. Physiol. Rev. 2014;94:355–382. doi: 10.1152/physrev.00030.2013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Brychta RJ, Chen KY. Cold-induced thermogenesis in humans. Eur. J. Clin. Nutr. 2017;71:345–352. doi: 10.1038/ejcn.2016.223. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Del Bene, V. E. in Clinical Methods: The History, Physical, and Laboratory Examinations (eds H. K. Walker, W. D. Hall, & J. W. Hurst) (Butterworths, 1990). [PubMed]
  • 46.Hanna EG, Tait PW. Limitations to thermoregulation and acclimatization challenge human adaptation to global warming. Int. J. Environ. Res. Public Health. 2015;12:8034–8074. doi: 10.3390/ijerph120708034. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Landsberg L. Core temperature: A forgotten variable in energy expenditure and obesity? Obes Rev. 2012;13(Suppl 2):97–104. doi: 10.1111/j.1467-789X.2012.01040.x. [DOI] [PubMed] [Google Scholar]
  • 48.Lawlor, D. A., Harbord, R. M., Sterne, J. A., Timpson, N. & Davey Smith, G. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med.27, 1133–1163 (2008). [DOI] [PubMed]
  • 49.Bowden J, et al. Assessing the suitability of summary data for two-sample Mendelian randomization analyses using MR-Egger regression: the role of the I2 statistic. Int. J. Epidemiol. 2016;45:1961–1974. doi: 10.1093/ije/dyw220. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Schooling CM, et al. Use of multivariable mendelian randomization to address biases due to competing risk before recruitment. Front. Genet. 2020;11:610852. doi: 10.3389/fgene.2020.610852. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.da Rocha EE, Alves VG, Silva MH, Chiesa CA, da Fonseca RB. Can measured resting energy expenditure be estimated by formulae in daily clinical nutrition practice? Curr. Opin. Clin. Nutr. Metab. Care. 2005;8:319–328. doi: 10.1097/01.mco.0000165012.77567.1e. [DOI] [PubMed] [Google Scholar]
  • 52.Burgess S, Davies NM, Thompson SG. Bias due to participant overlap in two-sample Mendelian randomization. Genet. Epidemiol. 2016;40:597–608. doi: 10.1002/gepi.21998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Minelli C, et al. The use of two-sample methods for Mendelian randomization analyses on single large datasets. Int. J. Epidemiol. 2021;50:1651–1659. doi: 10.1093/ije/dyab084. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Lopez PM, Subramanian SV, Schooling CM. Effect measure modification conceptualized using selection diagrams as mediation by mechanisms of varying population-level relevance. J. Clin. Epidemiol. 2019;113:123–128. doi: 10.1016/j.jclinepi.2019.05.005. [DOI] [PubMed] [Google Scholar]
  • 55.Neale Lab. UKBB GWAS Imputed v3 - File Manifest Release 20180731. http://www.nealelab.is/uk-biobank/ (2018).
  • 56.Sudlow C, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 2015;12:e1001779. doi: 10.1371/journal.pmed.1001779. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Pilling LC, et al. Human longevity: 25 genetic loci associated in 389,166 UK biobank participants. Aging (Albany NY). 2017;9:2504–2520. doi: 10.18632/aging.101334. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Deelen J, et al. A meta-analysis of genome-wide association studies identifies multiple longevity genes. Nat Commun. 2019;10:3669. doi: 10.1038/s41467-019-11558-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Hemani G, et al. The MR-Base platform supports systematic causal inference across the human phenome. Elife. 2018;7:e34408. doi: 10.7554/eLife.34408. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Palmer TM, et al. Instrumental variable estimation of causal risk ratios and causal odds ratios in Mendelian randomization analyses. Am. J. Epidemiol. 2011;173:1392–1403. doi: 10.1093/aje/kwr026. [DOI] [PubMed] [Google Scholar]
  • 61.Burgess S, et al. Using published data in Mendelian randomization: A blueprint for efficient identification of causal risk factors. Eur. J. Epidemiol. 2015;30:543–552. doi: 10.1007/s10654-015-0011-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Bowden J, et al. A framework for the investigation of pleiotropy in two-sample summary data Mendelian randomization. Stat. Med. 2017;36:1783–1802. doi: 10.1002/sim.7221. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Yavorska OO, Burgess S. MendelianRandomization: an R package for performing Mendelian randomization analyses using summarized data. Int. J. Epidemiol. 2017;46:1734–1739. doi: 10.1093/ije/dyx034. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Greco MF, Minelli C, Sheehan NA, Thompson JR. Detecting pleiotropy in Mendelian randomisation studies with summary data and a continuous outcome. Stat. Med. 2015;34:2926–2940. doi: 10.1002/sim.6522. [DOI] [PubMed] [Google Scholar]
  • 65.Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat. Genet. 2018;50:693–698. doi: 10.1038/s41588-018-0099-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.Zhao, Q., Wang, J., Hemani, G., Bowden, J. & Small, D. S. Statistical inference in two-sample summary-data Mendelian randomization using robust adjusted profile score. Arxiv.1801.09652 (2019).
  • 67.Bowden, J., Davey Smith, G., Haycock, P. C. & Burgess, S. Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. Genet Epidemiol.40, 304–314 (2016). [DOI] [PMC free article] [PubMed]
  • 68.Bowden, J., Davey Smith, G. & Burgess, S. Mendelian randomization with invalid instruments: Effect estimation and bias detection through Egger regression. Int. J. Epidemiol.44, 512–525 (2015). [DOI] [PMC free article] [PubMed]
  • 69.Timmers PR, et al. Genomics of 1 million parent lifespans implicates novel pathways and common diseases and distinguishes survival chances. Elife. 2019;8:1. doi: 10.7554/eLife.39856. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70.Paternoster R, Brame R, Mazerolle P, Piquero A. Using the correct statistical test for the equality of regression coefficients. Criminology. 1998;36:859–866. doi: 10.1111/j.1745-9125.1998.tb01268.x. [DOI] [Google Scholar]
  • 71.Anonymous. Online sample size and power calculator for Mendelian randomization with a binary outcome. https://sb452.shinyapps.io/power/ (2021).
  • 72.Freeman G, Cowling BJ, Schooling CM. Power and sample size calculations for Mendelian randomization studies using one genetic instrument. Int. J. Epidemiol. 2013;42:1157–1163. doi: 10.1093/ije/dyt110. [DOI] [PubMed] [Google Scholar]
  • 73.Del Greco MF, et al. Serum iron level and kidney function: A Mendelian randomization study. Nephrol. Dial. Transplant. 2017;32:273–278. doi: 10.1093/ndt/gfw215. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Tables. (107.5KB, xlsx)

Data Availability Statement

The datasets generated during and/or analyzed during the current study are available from the website of the Neale Lab (http://www.nealelab.is/uk-biobank/), a GWAS of parental attained age (https://figshare.com/articles/dataset/Plling_et_al_2017_UKB_parents_attained_age_GWAS/5439382/2), and a GWAS of survival to old age (https://www.ebi.ac.uk/gwas/publications/31413261).


Articles from Scientific Reports are provided here courtesy of Nature Publishing Group

RESOURCES